Selected Key Figures

  • Sales

    Key figure Sales (bar chart)Key figure Sales (bar chart) Inactive key figure Sales (bar chart)Inactive key figure Sales (bar chart)
  • EBITDA Before Special Items

    Key figure EBITDA margin (bar chart)Key figure EBITDA margin (bar chart) Inactive key figure EBITDA margin (bar chart)Inactive key figure EBITDA margin (bar chart)
  • Net income

    Inactive key figure Net income (bar chart)Inactive key figure Net income (bar chart) Key figure Net income (bar chart)Key figure Net income (bar chart)

+1.9%

The Bayer Group increased sales by 1.9% (Fx & portfolio adj.) to €12.2 billion in the second quarter of 2017.

View all Q2 key figures

+0.1%

At €3,056 million, EBITDA before special items of the Bayer Group matched the prior-year level (+ 0.1%).

View all Q2 key figures

€1.2 billion

Including a financial result of minus €405 million (Q2 2016: minus €314 million), income before income taxes was €1,746 million (Q2 2016: €1,824 million). After income tax expense of €417 million (Q2 2016: €431 million) and adjusting for income from discontinued operations after income taxes and noncontrolling interest, net income for the second quarter of 2017 amounted to €1,224 million (Q2 2016: €1,380 million).

View all Q2 key figures

Business Development of the Divisions

Pharmaceuticals

Pharmaceuticals sales developed positively in all regions. Sales of Pharmaceuticals rose by 5.8 percent (Fx & portfolio adj.) to €8,567 million in the first half of 2017. Our key growth products Xarelto™, Eylea™, Stivarga™, Xofigo™ and Adempas™ delivered strong performance, with their combined sales rising by 18.2 percent (Fx adj.) to €3,000 million (H1 2016: €2,519 million).

Find out more

Consumer Health

In the first half of 2017, Consumer Health posted sales of €3,143 million (Fx & portfolio adj. + 0.2 percent). Business developed positively in Europe in particular, while sales fell in North America due to a difficult market environment in the United States.

Find out more

Crop Science

Sales of Crop Science in the first half of 2017 declined by 5.4 percent (Fx & portfolio adj.) to €5,283 million. Sales fell at Fungicides and Insecticides in particular due to the adjustments made to provisions for product returns and weak business in Brazil. Higher sales in North America and Europe / Middle East / Africa were insufficient to offset the substantial decline in business in Latin America. Sales in Asia / Pacific came in at the prior-year level.

Find out more